Clinical Trial Update: Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus [Phase 1]

View source ↗

Summary

Phase 1 repeat-dose trial of bavituximab in patients co-infected with hepatitis C and HIV has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Hepatitis C

Drugs mentioned

• Bavituximab (bavituximab)

Snippet

Sponsor: Peregrine Pharmaceuticals | Conditions: Hepatitis C Virus, Hiv Infections | Phase 1 | Status: COMPLETED